Will you offer durva-FLOT perioperatively for adenocarcinoma of the esophagus?   

In the exploratory analysis, this population didn't seem to benefit. Is there sufficient evidence to recommend perioperative FLOT ± durvalumab over neoadjuvant chemoradiation followed by resection for patients with limited disease?  Would you factor in PDL1/TAP/CPS?